Trial Profile
Dasatinib first-line treatment in gastrointestinal stromal tumors. A multi center phase II trial.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- 18 Jan 2019 Status changed from discontinued to completed.
- 09 Jan 2018 Results published in the Cancer
- 17 Feb 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2018.